DE69129953D1 - Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus - Google Patents

Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus

Info

Publication number
DE69129953D1
DE69129953D1 DE69129953T DE69129953T DE69129953D1 DE 69129953 D1 DE69129953 D1 DE 69129953D1 DE 69129953 T DE69129953 T DE 69129953T DE 69129953 T DE69129953 T DE 69129953T DE 69129953 D1 DE69129953 D1 DE 69129953D1
Authority
DE
Germany
Prior art keywords
bisphosphonic acid
metabolism disorders
calcium metabolism
treat calcium
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69129953T
Other languages
English (en)
Other versions
DE69129953T2 (de
Inventor
Gerald S Brenner
Drazen Ostovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69129953D1 publication Critical patent/DE69129953D1/de
Application granted granted Critical
Publication of DE69129953T2 publication Critical patent/DE69129953T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69129953T 1990-01-31 1991-01-30 Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus Expired - Lifetime DE69129953T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47298790A 1990-01-31 1990-01-31
US56102690A 1990-08-01 1990-08-01

Publications (2)

Publication Number Publication Date
DE69129953D1 true DE69129953D1 (de) 1998-09-17
DE69129953T2 DE69129953T2 (de) 1999-04-15

Family

ID=27043979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129953T Expired - Lifetime DE69129953T2 (de) 1990-01-31 1991-01-30 Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus

Country Status (4)

Country Link
EP (1) EP0449405B1 (de)
JP (1) JP3033783B2 (de)
CA (1) CA2035179C (de)
DE (1) DE69129953T2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
WO1996035407A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
US6903194B1 (en) 1996-09-26 2005-06-07 Chungai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
US20020165363A1 (en) 1997-05-15 2002-11-07 Koh Sato Cachexia remedy
IT1296495B1 (it) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
TWI255718B (en) 1999-07-02 2006-06-01 Chugai Pharmaceutical Co Ltd Ameliorative agent for low vasopressin concentration
AU5849700A (en) * 1999-07-06 2001-01-22 Chugai Seiyaku Kabushiki Kaisha Remedies for drug-resistant hypercalcemia
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
WO2001082968A1 (fr) 2000-04-28 2001-11-08 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de proliferation cellulaire
JP3923800B2 (ja) 2000-05-05 2007-06-06 エフ．ホフマン−ラ ロシュ アーゲー ビスホスホン酸またはそれらの塩を含む、皮下投与のためのゲル様医薬組成物
CA2438208A1 (en) * 2001-02-07 2002-08-15 Durect Corporation Devices and methods for management of bone density
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3583887D1 (de) * 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.

Also Published As

Publication number Publication date
JP3033783B2 (ja) 2000-04-17
CA2035179A1 (en) 1991-08-01
CA2035179C (en) 2001-08-14
EP0449405B1 (de) 1998-08-12
JPH04211015A (ja) 1992-08-03
DE69129953T2 (de) 1999-04-15
EP0449405A2 (de) 1991-10-02
EP0449405A3 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
DE69129953D1 (de) Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69034018T2 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
ES8706707A1 (es) Procedimiento para la obtencion de 3-amino-1-hidroxi-propan-1,1-difosfonato disordico
DE69004081D1 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69526437T2 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
ATE71629T1 (de) Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels.
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69323303D1 (de) Zusammensetzungen zur Behandlung des trockenen Auges
DE69214610D1 (de) Verfahren zur Behandlung von Erdgas
DE3883606D1 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69627708T2 (de) Verwendung von fluorhaltige tenside enthaltenden zusammensetzungen zur beherrschung des biobewuchses
DE68907386D1 (de) Verwendung von phytinsaeure oder deren salzen zur verhinderung oder behandlung von lebererkrankungen.
PT80152A (de) Methode zur behandlung des glaukoms vok
NO944500D0 (no) Tiosubstituerte cykliske fosfonatforbindelser for å behandle unormal kalsium- og fosfatmetabolisme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US